Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 319

1.

Effect of vitreomacular adhesion on antivascular endothelial growth factor therapy for macular edema secondary to branch retinal vein occlusion.

Terao R, Yuda K, Kure K, Inoue T, Ohtsu H, Yanagi Y.

Jpn J Ophthalmol. 2014 Mar;58(2):139-45. doi: 10.1007/s10384-013-0302-4. Epub 2014 Jan 10.

PMID:
24402616
2.

Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion.

Jaissle GB, Szurman P, Feltgen N, Spitzer B, Pielen A, Rehak M, Spital G, Heimann H, Meyer CH; Retinal Vein Occlusion Study Group.

Graefes Arch Clin Exp Ophthalmol. 2011 Feb;249(2):183-92. doi: 10.1007/s00417-010-1470-2. Epub 2010 Aug 18.

3.

Correlation between optical coherence tomographic hyperreflective foci and visual outcomes after intravitreal bevacizumab for macular edema in branch retinal vein occlusion.

Kang JW, Lee H, Chung H, Kim HC.

Graefes Arch Clin Exp Ophthalmol. 2014 Sep;252(9):1413-21. doi: 10.1007/s00417-014-2595-5. Epub 2014 Mar 1.

PMID:
24577742
4.

Spectral-domain optical coherence tomography (SD-OCT) patterns and response to intravitreal bevacizumab therapy in macular edema associated with branch retinal vein occlusion.

Kang HM, Chung EJ, Kim YM, Koh HJ.

Graefes Arch Clin Exp Ophthalmol. 2013 Feb;251(2):501-8. doi: 10.1007/s00417-012-2067-8. Epub 2012 Jun 1.

PMID:
22653439
5.

Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.

Puche N, Glacet A, Mimoun G, Zourdani A, Coscas G, Soubrane G.

Acta Ophthalmol. 2012 Jun;90(4):357-61. doi: 10.1111/j.1755-3768.2010.01913.x. Epub 2010 Jun 29.

6.

Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration.

Lee SJ, Koh HJ.

Ophthalmology. 2011 Jan;118(1):101-10. doi: 10.1016/j.ophtha.2010.04.015. Epub 2010 Aug 3.

PMID:
20678805
7.

Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year.

Kriechbaum K, Prager F, Geitzenauer W, Benesch T, Schütze C, Simader C, Schmidt-Erfurth U.

Ophthalmology. 2009 Dec;116(12):2415-21. doi: 10.1016/j.ophtha.2009.05.001. Epub 2009 Sep 10.

PMID:
19744723
8.

Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.

Wu L, Arevalo JF, Berrocal MH, Maia M, Roca JA, Morales-Cantón V, Alezzandrini AA, Díaz-Llopis MJ.

Retina. 2010 Jul-Aug;30(7):1002-11. doi: 10.1097/IAE.0b013e3181cea68d.

PMID:
20616679
9.

Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.

Ding X, Li J, Hu X, Yu S, Pan J, Tang S.

Retina. 2011 May;31(5):838-45. doi: 10.1097/IAE.0b013e3181f4420d.

PMID:
21293319
10.

Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion.

Hoeh AE, Ach T, Schaal KB, Scheuerle AF, Dithmar S.

Graefes Arch Clin Exp Ophthalmol. 2009 Dec;247(12):1635-41. doi: 10.1007/s00417-009-1151-1. Epub 2009 Jul 26.

PMID:
19633982
11.

Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion.

Ehlers JP, Decroos FC, Fekrat S.

Retina. 2011 Oct;31(9):1856-62. doi: 10.1097/IAE.0b013e31820d59a5.

PMID:
21659943
12.

Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.

Wu L, Arevalo JF, Roca JA, Maia M, Berrocal MH, Rodriguez FJ, Evans T, Costa RA, Cardillo J; Pan-American Collaborative Retina Study Group (PACORES).

Retina. 2008 Feb;28(2):212-9. doi: 10.1097/IAE.0b013e3181619bee.

PMID:
18301025
13.

Intravitreal bevacizumab associated with grid laser photocoagulation in macular edema secondary to branch retinal vein occlusion.

Salinas-Alamán A, Zarranz-Ventura J, Caire González-Jauregui JM, Sádaba-Echarri LM, Barrio-Barrio J, García-Layana A.

Eur J Ophthalmol. 2011 Jul-Aug;21(4):434-9. doi: 10.5301/EJO.2010.6101.

14.

Effect of Vitreomacular Adhesion on Treatment Outcomes in the Ranibizumab for Edema of the Macula in Diabetes (READ-3) Study.

Sadiq MA, Soliman MK, Sarwar S, Agarwal A, Hanout M, Demirel S, Rentiya ZS, Khan W, Do DV, Nguyen QD, Sepah YJ; READ-3 Study Group.

Ophthalmology. 2016 Feb;123(2):324-9. doi: 10.1016/j.ophtha.2015.09.032. Epub 2015 Oct 29.

PMID:
26520169
15.

Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion.

Chung EJ, Hong YT, Lee SC, Kwon OW, Koh HJ.

Graefes Arch Clin Exp Ophthalmol. 2008 Sep;246(9):1241-7. doi: 10.1007/s00417-008-0866-8. Epub 2008 Jun 11.

PMID:
18546006
16.

Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.

Mayer WJ, Remy M, Wolf A, Kook D, Kampik A, Ulbig M, Reznicek L, Haritoglou C.

Ophthalmologica. 2012;228(2):110-6. doi: 10.1159/000338732. Epub 2012 Jun 23.

PMID:
22739239
17.

The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion.

Ahmadi AA, Chuo JY, Banashkevich A, Ma PE, Maberley DA.

Can J Ophthalmol. 2009 Apr;44(2):154-9. doi: 10.3129/i09-040.

PMID:
19491948
18.

Intravitreal bevacizumab combined with grid photocoagulation in recurrent macular edema secondary to retinal vein occlusion.

Farese E, Cennamo G, Velotti N, Traversi C, Rinaldi M, De Crecchio G.

Eur J Ophthalmol. 2014 Sep-Oct;24(5):761-70. doi: 10.5301/ejo.5000448. Epub 2014 Feb 26.

PMID:
24585424
19.

Ranibizumab for serous macular detachment in branch retinal vein occlusions.

Gallego-Pinazo R, Dolz-Marco R, Pardo-López D, Martínez-Castillo S, Lleó-Pérez A, Arévalo JF, Díaz-Llopis M.

Graefes Arch Clin Exp Ophthalmol. 2013 Jan;251(1):9-14. doi: 10.1007/s00417-012-2023-7. Epub 2012 Apr 25.

PMID:
22527327
20.

Influence of the vitreomacular interface on the efficacy of intravitreal therapy for uveitis-associated cystoid macular oedema.

Munk MR, Ram R, Rademaker A, Liu D, Setlur V, Chau F, Schmidt-Erfurth U, Goldstein DA.

Acta Ophthalmol. 2015 Nov;93(7):e561-7. doi: 10.1111/aos.12699. Epub 2015 Feb 23.

Supplemental Content

Support Center